SCHEMBL30462034

SCHEMBL30462034

Cn1cc(C(F)F)nc1-c1ccc(CNc2nc(Cl)nc3ccoc23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 3/20 0.39
▸ WDR48 Q8TAF3 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ PDE5A O76074 1/20 0.37
▸ APP P05067 1/20 0.37
▸ PDE2A O00408 2/20 0.34
▸ CDK1 P06493 2/20 0.34
▸ CCNE2 O96020 2/20 0.34
▸ CCNE1 P24864 2/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ ESR1 P03372 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ JAK2 O60674 1/20 0.30
▸ ABL1 P00519 1/20 0.30
▸ INSR P06213 1/20 0.30
▸ LCK P06239 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30462003 0.85 PDE2A (0.40) USP1WDR48PDE4APDE4BPDE4C
SCHEMBL31423623 0.77 USP1 (0.43) USP1WDR48
SCHEMBL30461987 0.76 CCNE2 (0.41) USP1WDR48PDE5APDE2ACDK1
SCHEMBL29043902 0.76 CCNE2 (0.41) USP1WDR48PDE5APDE2ACDK1
SCHEMBL31423555 0.76 USP1 (0.46) USP1WDR48
SCHEMBL26660000 0.73 APP (0.67) USP1WDR48PDE4APDE4BPDE4C
SCHEMBL31690997 0.73 APP (0.67) USP1WDR48PDE4APDE4BPDE4C
SCHEMBL31691093 0.72 PDE5A (0.50) USP1WDR48PDE4APDE4BPDE4C
SCHEMBL31423613 0.70 USP1 (0.41) USP1WDR48
SCHEMBL26627785 0.70 PDE5A (0.47) USP1WDR48PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741386-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-13 — — EP disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 — — US disclosed
EP-4516779-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-03-05 — — EP disclosed
WO-2025007777-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-09 — — WO disclosed
CN-118660872-A Pyrimidine compound, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2024-09-17 — — CN disclosed
CN-116496252-A Pyrimidine compound, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2023-07-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF USP1, UPP1, UFL1 USP1 1/4885WDR48 1343/4885PDE4A 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback